May 2026 Research Update

This month added clearer signals that getting the cause of pulmonary alveolar proteinosis (PAP) right can depend on targeted testing, and that different tests answer different questions. One study focused on detecting autoimmune PAP using a blood antibody test, while another showed that in children with interstitial lung disease, PAP was one of the conditions most likely to have a genetic explanation. Together, these studies highlight that PAP is not one single disease and that sorting out the cause can be very test-dependent. [1] [2]

A diagnostic assay study reported that a bioluminescent immunoassay could match gold-standard testing when measuring GM-CSF autoantibodies, which are central to diagnosing autoimmune PAP. In that report, all clinically confirmed autoimmune PAP cases tested positive, and the assay also separated 24 blinded disease-control samples from autoimmune PAP with 100% accuracy versus the reference method. The same study also noted positive results in some people with disseminated Cryptococcus or Nocardia infections, which matters because it suggests results may sometimes appear outside classic autoimmune PAP and may need careful interpretation in the setting of certain infections. [1]

In a large cohort of 1,693 children with childhood interstitial lung disease, investigators reported that genetic testing had an average diagnostic yield of 50.8%, and the yield was highest in the subgroup labeled pulmonary alveolar proteinosis at 87.1%. The study also reported that having two or more non-pulmonary organ manifestations made an underlying systemic disease more likely by about three- to five-fold. For families facing possible PAP in childhood, this reinforces that looking beyond the lungs and considering genetics can be especially important for understanding what type of PAP is present. [2]

For patients and caregivers, these studies mainly add understanding of how PAP can be classified rather than changing treatment on their own. The blood test work supports progress toward easier testing for autoimmune PAP, but it also raises a practical uncertainty: some infections may show positive signals, so results may not always be straightforward in complex cases. The childhood cohort results strengthen the idea that, in children especially, finding an underlying cause is often possible and may depend on whether other organs are affected, though the study does not say how often specific genes change care for an individual child. [1] [2]

This month, animal research leaned into a single picture: PAP-like surfactant build-up can worsen when lung cleanup cells (alveolar macrophages) do not mature properly or cannot process surfactant well. Two different lines of work tried to change that biology, either by adjusting cell stress pathways in a lung injury model or by delivering GM-CSF through an experimental nasal gene-delivery approach. These are early studies that help explain possible mechanisms and test ideas, but they do not predict how well approaches will work in people. [3] [4] [5]

One mouse study separated the roles of two related low-oxygen response proteins (HIF-1alpha and HIF-2alpha) inside alveolar macrophages. Either one alone impaired macrophage maturation, and full rescue required deleting both in the model, suggesting these pathways can hold macrophages back from becoming fully functional. The authors also reported that stabilizing HIF-2alpha reduced surfactant clearance in a mouse model of PAP, connecting a specific metabolic program to the ability to clear surfactant. [3]

A separate rat study modeled indium-related lung disease with features that included alveolar proteinosis markers, and reported that sulforaphane reduced inflammation, oxidative stress, and vascular remodeling in that setting. The study linked these changes to activating Nrf2 and inhibiting NF-kappaB, and it reported reductions in several measured markers related to protein build-up and fibrosis in the lungs. This work is about a specific toxic exposure model rather than classic autoimmune PAP, but it adds to the broader idea that inflammatory and oxidative stress pathways can shape PAP-like lung changes in some conditions. [4]

Another mouse study tested a nose-only, small-volume intranasal gene-delivery method designed to produce secreted therapeutic proteins, including GM-CSF. The authors reported that GM-CSF made this way reached the lungs and partially improved PAP-related biomarkers such as cloudy lung wash fluid and staining that reflects protein build-up. They also reported that higher-dose GM-CSF dosing led to lung consolidation and morbidity in some mice, while lower doses had more favorable short-term safety signals, making dose and safety a central open question. [5]

For patients, these studies are best viewed as early-stage steps that explain biology and try out possible future approaches. The macrophage metabolism work helps clarify why PAP can persist when these cells cannot clear surfactant, but it does not identify a ready-to-use test or treatment. The sulforaphane and intranasal GM-CSF gene-delivery results show that PAP-like markers can move in the right direction in animal models, yet key uncertainties remain about translation to humans, including dosing and longer-term safety. [3] [4] [5]

This month also included single-patient reports that underline how different PAP can look depending on the underlying cause. One case tied PAP to a rare immune disorder and described improvement after addressing that root problem, while another showed that PAP without GM-CSF antibodies can be mistaken for repeated infections and still improve with a standard lung-washing procedure. These reports do not prove what will happen for most people, but they make the range of real-world presentations easier to picture. [6] [7]

In one patient with ADA-SCID (a severe immune deficiency), PAP was reported and then successfully treated after gene therapy for the immune disorder. The report supports the idea that in secondary forms of PAP, treating the underlying condition can matter as much as treating the lung findings. The summary provided does not include details like timing or how improvement was measured, so the size and durability of the response are not clear from this report alone. [6]

Another case described a 79-year-old woman whose PAP was anti-GM-CSF-negative and initially misdiagnosed as recurrent pneumonia. After two sequential whole-lung lavages, the report described improvement in symptoms and lung imaging by 6 months, with oxygen levels reported as improved on room air. Genetic testing was not available, so hereditary PAP could not be fully ruled out, which keeps the exact type of PAP uncertain in this case. [7]

For patients and caregivers, these case reports mainly reinforce two practical points about uncertainty in PAP: the cause can be very different from person to person, and the diagnosis can be missed when symptoms resemble pneumonia. They also show that improvement can be reported in very different settings, including after whole-lung lavage and after treating an underlying immune deficiency, but a single case cannot predict outcomes for others. The key open question these reports leave is how to reliably identify the exact PAP subtype when antibody tests are negative or when genetic testing is not performed. [6] [7]